Cargando…
Transcription Factors in Cancer Development and Therapy
Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithel...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464564/ https://www.ncbi.nlm.nih.gov/pubmed/32824207 http://dx.doi.org/10.3390/cancers12082296 |
_version_ | 1783577394610700288 |
---|---|
author | Vishnoi, Kanchan Viswakarma, Navin Rana, Ajay Rana, Basabi |
author_facet | Vishnoi, Kanchan Viswakarma, Navin Rana, Ajay Rana, Basabi |
author_sort | Vishnoi, Kanchan |
collection | PubMed |
description | Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial–mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs. |
format | Online Article Text |
id | pubmed-7464564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74645642020-09-04 Transcription Factors in Cancer Development and Therapy Vishnoi, Kanchan Viswakarma, Navin Rana, Ajay Rana, Basabi Cancers (Basel) Review Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial–mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs. MDPI 2020-08-15 /pmc/articles/PMC7464564/ /pubmed/32824207 http://dx.doi.org/10.3390/cancers12082296 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vishnoi, Kanchan Viswakarma, Navin Rana, Ajay Rana, Basabi Transcription Factors in Cancer Development and Therapy |
title | Transcription Factors in Cancer Development and Therapy |
title_full | Transcription Factors in Cancer Development and Therapy |
title_fullStr | Transcription Factors in Cancer Development and Therapy |
title_full_unstemmed | Transcription Factors in Cancer Development and Therapy |
title_short | Transcription Factors in Cancer Development and Therapy |
title_sort | transcription factors in cancer development and therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464564/ https://www.ncbi.nlm.nih.gov/pubmed/32824207 http://dx.doi.org/10.3390/cancers12082296 |
work_keys_str_mv | AT vishnoikanchan transcriptionfactorsincancerdevelopmentandtherapy AT viswakarmanavin transcriptionfactorsincancerdevelopmentandtherapy AT ranaajay transcriptionfactorsincancerdevelopmentandtherapy AT ranabasabi transcriptionfactorsincancerdevelopmentandtherapy |